FDA 483 - Clavmed - October 29, 2025

Clavmed, a contract manufacturer in Tuszyn, Poland, was inspected by the FDA and found to have a significant lack of established quality system procedures and instructions. This deficiency impacts numerous critical areas including quality audits, change controls, process validation, and complaint handling. The findings indicate a fundamental absence of a robust quality management system at the firm.